Post PCI Antiplatelet Strategy Selection Tool
Clinical assessment
Enter the current post-PCI context to review antiplatelet strategy considerations.
Clinical context
Antithrombotic treatment after PCI should balance recurrent ischemic events and stent thrombosis against bleeding. This tool organizes selected factors; it does not calculate a validated risk score or prescribe a drug regimen.
General principles
- For ACS patients without high bleeding risk, DAPT with aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy.
- Selected patients may benefit from a bleeding-reduction strategy, including P2Y12-inhibitor monotherapy or abbreviated DAPT, depending on the agent, timing, clinical stability, and guideline criteria.
- When long-term oral anticoagulation is indicated, minimize triple-therapy exposure; the duration of aspirin and the subsequent regimen depend on individual ischemic and bleeding risks.
- Beyond 12 months, consider extended antithrombotic therapy only after explicit individualized assessment and shared decision-making.
Important limitations
The inputs “high bleeding risk” and “high ischemic risk” are broad categories and are not independently validated by this tool. It does not account for every drug contraindication, dose adjustment, adherence issue, stent characteristic, procedural complication, or patient preference.
Guideline references
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
J Am Coll Cardiol. DOI: 10.1016/j.jacc.2024.11.009
2023 ESC Guidelines for the management of acute coronary syndromes.
Eur Heart J. DOI: 10.1093/eurheartj/ehad191
Urban P, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium.
Circulation. 2019. DOI: 10.1161/CIRCULATIONAHA.119.040167
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.